전임상 CRO 시장 : 서비스 유형별, 모델 유형별, 분자 유형별, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Preclinical CRO Market is projected to grow by USD 12.76 billion at a CAGR of 8.93% by 2032.

The preclinical CRO market is central to how pharmaceutical, biotechnology, and academic sponsors convert validated biology into investigational new drug, or IND, packages. Demand is anchored by regulated GLP toxicology, safety pharmacology, ADME/DMPK, bioanalysis, efficacy models, pathology, and CMC-adjacent analytical support required before first-in-human studies.

Growth is supported by sustained biomedical R&D spending, expanding biologics and advanced therapy pipelines, and the need for specialized infrastructure that many sponsors do not maintain in-house. Regulatory frameworks from the FDA, EMA, ICH, OECD, and national GLP authorities continue to make quality systems, data integrity, animal welfare, and translational relevance decisive differentiators for preclinical CRO partners.

Transformative Shifts in the Preclinical CRO Landscape

The preclinical CRO landscape is shifting from capacity-based outsourcing toward science-led, integrated development partnerships. Sponsors increasingly expect CROs to combine disease biology, model selection, toxicology strategy, biomarker development, bioanalytical validation, and regulatory documentation into a coordinated IND-enabling pathway.

Important structural changes include growth in biologics, cell and gene therapies, RNA-based medicines, radiopharmaceuticals, and complex immunology programs. The FDA Modernization Act 2.0 removed the statutory requirement that animal testing be used in every drug-development case, increasing attention on validated new approach methodologies while preserving the need for regulator-accepted evidence packages. This shift is accelerating interest in organ-on-chip systems, in silico toxicology, high-content imaging, and human-relevant translational models.

Cumulative Impact of Artificial Intelligence on Preclinical CROs

Artificial intelligence is changing preclinical CRO operations through target validation, compound prioritization, image analysis, pathology support, toxicology prediction, literature mining, dose optimization, and protocol design. These applications can reduce avoidable iteration when they are paired with curated datasets, domain expertise, audit trails, and human scientific review.

The cumulative impact is not the replacement of GLP studies, but a more evidence-rich design process. Regulators, including the FDA and EMA, have emphasized transparency, model governance, bias control, cybersecurity, traceability, and fit-for-purpose validation for AI-enabled tools. CROs that align AI with validated workflows, secure data environments, and quality management systems are better positioned to improve study reliability, reproducibility, and sponsor confidence.

Key Regional Insights for Preclinical CRO Services

North America remains a core preclinical CRO hub because the United States has deep venture financing, large pharmaceutical R&D operations, major academic medical centers, established GLP testing capacity, and direct proximity to FDA expectations. Canada contributes translational science, clinical research infrastructure, public life sciences programs, and cross-border collaboration with U.S. sponsors.

Europe is shaped by EMA coordination, national competent authorities, strong GLP laboratories, animal welfare regulation, and established pharmaceutical clusters in Germany, France, the United Kingdom, Italy, and Spain. Asia-Pacific is expanding through China, India, Japan, South Korea, Australia, and ASEAN countries, supported by cost-efficient operations, maturing regulatory systems, chemistry and biologics capabilities, and rising domestic innovation. Latin America is developing through Brazil and Mexico, where healthcare demand, local manufacturing policies, and academic research networks support regional service opportunities. The Middle East is building biotechnology and healthcare research capacity through national diversification agendas, particularly in Gulf economies, while Africa is gradually strengthening biomedical research infrastructure through public health research, university partnerships, and disease-area specialization.

Key Economic and Strategic Group Insights

Within ASEAN, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and the Philippines support regional life sciences growth through manufacturing investment, university research, improving clinical ecosystems, and regulatory modernization. Singapore is especially important for biomedical research coordination, while larger ASEAN markets contribute patient access, manufacturing depth, and expanding scientific talent. The GCC is building healthcare and biotechnology capacity through national diversification strategies, with Saudi Arabia and the United Arab Emirates emphasizing research infrastructure, advanced medicine access, genomics initiatives, and public-private health innovation.

The European Union benefits from harmonized regulatory pathways, Horizon Europe funding, high pharmacovigilance standards, data protection requirements, and strong quality expectations that influence preclinical CRO vendor qualification. BRICS countries add scale, scientific talent, chemistry capabilities, and growing domestic demand, with China, India, and Brazil especially relevant to outsourcing, manufacturing, and translational research. The G7 continues to anchor high-value innovation, intellectual property protection, mature regulatory systems, and advanced biomedical funding. NATO markets provide resilient research supply chains for allied healthcare priorities, although preclinical testing, GLP oversight, and drug development requirements remain governed by national and regional regulators.

Key Country Insights Across Major Preclinical CRO Markets

The United States leads through FDA-regulated development pathways, biotech financing, academic discovery networks, and large-scale outsourcing demand. Canada offers translational research and clinical connectivity, while Mexico and Brazil support regional access, manufacturing links, and expanding life sciences investment. The United Kingdom remains influential through MHRA expertise, the Golden Triangle research base, advanced therapy development, and strong university-industry collaboration.

Germany, France, Italy, and Spain provide strong pharmaceutical manufacturing, toxicology, bioanalysis, and academic ecosystems supported by national research institutions and EU-aligned quality expectations. Russia retains scientific capacity but faces market-access, logistics, and sanctions-related constraints that affect international collaboration. China and India are major growth engines through scale, medicinal chemistry, biologics, biosimilars, and cost-effective service capacity, while Japan, South Korea, and Australia contribute high-quality regulatory science, innovation incentives, advanced biomedical research, and specialized preclinical capabilities. South Korea is notable for biologics and cell therapy infrastructure, Japan for rigorous regulatory science and pharmaceutical innovation, and Australia for translational research networks and globally recognized study quality.

Actionable Recommendations for Industry Leaders

Industry leaders should select preclinical CRO partners based on scientific relevance, GLP compliance history, data integrity controls, animal welfare standards, model validity, and regulatory writing capability rather than cost alone. Early alignment on ICH M3(R2), safety pharmacology, genetic toxicology, reproductive toxicology, immunogenicity, bioanalytical methods, and species selection can prevent costly protocol redesign.

Executives should also build dual-source capacity for critical assays, qualify AI-enabled workflows, and require transparent study governance. Strategic CRO relationships should include milestone-based oversight, quality audits, cybersecurity requirements, biomarker strategy, sample-chain controls, and escalation procedures for unexpected findings. Sponsors that integrate CROs earlier in candidate selection can improve IND readiness, strengthen translational rationale, and reduce avoidable development risk.

Research Methodology and Evidence Base

This executive summary is built from verified public and industry sources, including regulatory guidance from the FDA, EMA, ICH, OECD GLP principles, national agency publications, clinical trial registries, scientific literature, public policy documents, and recognized life sciences reports. Insights were triangulated across regulatory, scientific, operational, and regional indicators.

The analysis prioritizes evidence that is observable and reproducible, including R&D investment patterns, therapeutic modality shifts, outsourcing drivers, quality-system expectations, AI governance principles, and regional capability development. No unsupported market estimates are used; emphasis is placed on documented regulatory changes, established preclinical requirements, and validated operational trends affecting CRO decision-making.

Conclusion: Strategic Outlook for Preclinical CROs

The preclinical CRO market is becoming more specialized, regulated, and technology-enabled as sponsors pursue complex therapies under tighter development timelines. CROs that combine GLP execution, translational science, bioanalytical depth, animal welfare discipline, and regulatory fluency are positioned to remain essential partners in drug development.

Artificial intelligence, new approach methodologies, and globalized outsourcing will continue to reshape study design, but the market will still reward defensible evidence, quality systems, reproducibility, and regulator-ready documentation. Sponsors that choose CRO partners strategically can improve program resilience, accelerate IND preparation, and strengthen the probability of successful clinical transition.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Preclinical CRO Market, by Service Type

• 7.1. Bioanalytical Services
  • 7.1.1. LC-MS/MS Bioanalysis
  • 7.1.2. Product Analysis
  • 7.1.3. Stability Testing
  • 7.1.4. Immunogenicity Testing
  • 7.1.5. Pharmacokinetics & Pharmacodynamics Testing
• 7.2. In Vivo & In Vitro Studies
• 7.3. Toxicology Testing
  • 7.3.1. General Toxicology
  • 7.3.2. Safety Pharmacology
  • 7.3.3. Reproductive Toxicology
  • 7.3.4. Juvenile Toxicology
  • 7.3.5. Carcinogenicity Studies
  • 7.3.6. Clinical Pathology Services
• 7.4. Drug Discovery Services
  • 7.4.1. Target ID & Validation
  • 7.4.2. High-Throughput Screening
  • 7.4.3. Fragment Screening
  • 7.4.4. Functional Genomics (CRISPR)
• 7.5. Chemistry, Manufacturing, and Controls (CMC)
  • 7.5.1. Formulation Development
  • 7.5.2. Impurity Testing
  • 7.5.3. GMP Manufacture & Packaging
  • 7.5.4. Clinical Supply Logistics

8. Preclinical CRO Market, by Model Type

• 8.1. Patient Derived Organoid (PDO) Model
• 8.2. Patient Derived Xenograft Model

9. Preclinical CRO Market, by Molecule Type

• 9.1. Small Molecule
• 9.2. Large Molecule

10. Preclinical CRO Market, by Application

• 10.1. Cardiology
• 10.2. Neurology
• 10.3. Oncology
• 10.4. Infectious Diseases
• 10.5. Metabolic Disorders

11. Preclinical CRO Market, by End User

• 11.1. Academic & Research Institutes
• 11.2. Biotechnology Companies
• 11.3. Pharmaceutical Companies

12. Preclinical CRO Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Preclinical CRO Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Preclinical CRO Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Charles River Laboratories International, Inc.
• 16.2. Laboratory Corporation of America Holdings
• 16.3. ICON PLC
• 16.4. WuXi AppTec Co., Ltd.
• 16.5. Syneos Health, Inc.
• 16.6. Eurofins Scientific SE
• 16.7. Thermo Fisher Scientific Inc.
• 16.8. Evotec SE
• 16.9. Pharmaron Beijing Co., Ltd.
• 16.10. Medpace Holdings, Inc.
• 16.11. SGS SA
• 16.12. Inotiv, Inc.
• 16.13. Genesis Biotechnology Group, LLC
• 16.14. Jubilant Biosys Ltd.
• 16.15. 10x Genomics, Inc.
• 16.16. Celerion Holdings, Inc.
• 16.17. Taconic Biosciences, Inc.
• 16.18. Atuka Inc.
• 16.19. BenchSci
• 16.20. Diag2Tec SAS
• 16.21. Hera Biolabs Inc. by Demeetra AgBio, Inc.
• 16.22. ImQuest BioSciences Inc. by Statera Biopharma, Inc.
• 16.23. Intertek Group PLC
• 16.24. IQVIA Inc.
• 16.25. JSR Corporation
• 16.26. MLM Medical Labs GmbH
• 16.27. Phenos GmbH
• 16.28. REPROCELL Inc.
• 16.29. Scantox Holding Aps
• 16.30. SCiAN Services Inc.